ArchivesMagazine - 01 Feb 2018Pelatro forecast to produce significant profit growth Analyst earnings estimates imply rapid growth for newly-listed marketing technology company 01 February 2018|Feature Issue: 01 Feb 2018 - Page 41 < Sterling bounce is a boon for Shoe Zone Pension cash withdrawals are falling, says the taxman > Issue: 01 Feb 2018 - Page 41 | Contents Next: Pension cash withdrawals are falling, says the taxman Previous: Sterling bounce is a boon for Shoe Zone Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Steven Frazer Issue Contents Editor's View Companies and investors need to avoid short-termism Feature Bitcoin blues: the end of cryptocurrency fever? Europe: So many reasons to invest now Beazley is a cyber security insurance leader Sterling bounce is a boon for Shoe Zone Threadbare margins in mobile payments Pelatro forecast to produce significant profit growth Kier’s 10% rally is not as impressive as some may think Vertu crashes after big slump in new car sales Pension power: will your employer pay into your SIPP? Funds Unicorn UK Growth Fund is a magical money-maker Great Ideas Molins changes its name to MPAC There is a good reason why Avesoro Resources' share price has 'shot up' Greencore's prospects clouded by currency risks Sopheon drip feeds the good news K3 Capital is hoovering up small cap M&A deals Value retailer B&M is strong and getting stronger NMC Health to benefit from growing UAE healthcare market Investment Trusts Is there more to come from top performer Phoenix Spree? News Currency movements imply potential weakness in many large cap stocks A ‘remarkable time’ to invest in UK income funds Renishaw’s rating haircut may not be over Dechra deals could create animal magic Lloyds has an under-appreciated business which could boost group profit Personal Finance Pension cash withdrawals are falling, says the taxman How to protect yourself from financial scams Under The Bonnet Why have shares in FTSE 100 pharma group Shire been falling since 2016? Week Ahead Get ready for the FTSE 100 pharma reporting season Can Babcock turn it around?